Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma

NCT ID: NCT01693068

Last Updated: 2018-01-05

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 194 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2012-12-05
• Study Completion Date: 2016-10-24

Brief Summary

This is a Phase 2, multicenter, randomized, controlled, open-label trial of pimasertib versus dacarbazine aimed to confirm the activity of pimasertib in previously untreated subjects with N-Ras mutated locally advanced or metastatic malignant cutaneous melanoma by comparing the progression-free survival (PFS) of subjects treated with either pimasertib or dacarbazine and by getting a better understanding of the efficacy, safety, pharmacogenomics (PGx) and their relationship with pimasertib exposure.

Conditions

N-Ras Mutated Locally Advanced or Metastasis Malignant Cutaneous Melanoma

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Pimasertib

Group Type: EXPERIMENTAL

Pimasertib

Intervention Type: DRUG

Subjects will receive pimasertib orally as monotherapy at a dose of 60 milligram (mg) twice daily continuously. Treatment will consist of repeated 21-day cycles which will continue until progression of the disease, unacceptable toxicity, withdrawal of informed consent, or death, whichever occurs first.

Dacarbazine

Group Type: ACTIVE_COMPARATOR

Dacarbazine

Intervention Type: DRUG

Subjects will receive dacarbazine intravenously at dose of 1000 milligram per square meter (mg/m\^2) of body surface area every 3 weeks on Day 1 of each 21-days cycle until progression of the disease, unacceptable toxicity, withdrawal of informed consent, or death, whichever occurs first. Eligible subjects with documented tumor progression on dacarbazine will offer to switch to pimasertib treatment.

Interventions

Pimasertib

Subjects will receive pimasertib orally as monotherapy at a dose of 60 milligram (mg) twice daily continuously. Treatment will consist of repeated 21-day cycles which will continue until progression of the disease, unacceptable toxicity, withdrawal of informed consent, or death, whichever occurs first.

Intervention Type: DRUG

Dacarbazine

Subjects will receive dacarbazine intravenously at dose of 1000 milligram per square meter (mg/m\^2) of body surface area every 3 weeks on Day 1 of each 21-days cycle until progression of the disease, unacceptable toxicity, withdrawal of informed consent, or death, whichever occurs first. Eligible subjects with documented tumor progression on dacarbazine will offer to switch to pimasertib treatment.

Intervention Type: DRUG

Other Intervention Names

MSC1936369B; AS703026

Eligibility Criteria

Inclusion Criteria

• Subjects with measurable, histologically or cytologically confirmed, locally advanced or metastatic cutaneous melanoma (stage III c or M1ac) N-Ras mutated. If N-Ras mutational status is unknown at screening, it must be prospectively defined before inclusion. If N-Ras mutational status is already known before screening, it must be retrospectively confirmed after inclusion by the sponsor.
• Tumor lesions amenable to biopsy or available tumor tissue as archival samples.
• Age greater than or equal to (>=) 18 years.
• Has read and understood the informed consent form and is willing and able to give informed consent. Fully understands requirements of the trial and willing to comply with all trial visits and assessments.
• Women of childbearing potential must have a negative blood pregnancy test at the screening visit. For the purposes of this trial, women of childbearing potential are defined as: "All female subjects after puberty unless they are post-menopausal for at least two years, or are surgically sterile".
• Female subjects of childbearing potential and male subjects with female partners of childbearing potential must be willing to avoid pregnancy by using an adequate method of contraception for 2 weeks prior to, during and four weeks after the last dose of trial medication. Effective contraception is defined as the method of contraception with a failure rate of less than 1% per year. Adequate contraception is defined as follows: two barrier methods or one barrier method with a spermicidal or intrauterine device or oral contraception for female partners of male subjects.

Exclusion Criteria

• Has previous systemic treatment for locally advanced or metastatic cutaneous melanoma (excluding adjuvant treatment).
• Has non-measurable lesions, disease not evaluable by Response Evaluation Criteria in Solid Tumors (RECIST) v. 1.1
• Has an Eastern Cooperative Oncology Group performance status (ECOG PS) >1.
• Has bone marrow impairment as evidenced by Hemoglobin <10.0 g/dL, Neutrophil count <1.5 * 10^9/L, platelets <100 * 10^9/L.
• Has renal impairment as evidenced by calculated creatinine clearance <60 mL/min (according to the Cockcroft-Gault formula).
• Has liver function abnormality as defined by total bilirubin >1.5 * Upper Limit of Normal (ULN), or aspartate aminotransferase (AST)/alanine aminotransferase (ALT) >2.5 * ULN, for subjects with liver involvement AST/ALT >5 * ULN.
• Has significant cardiac conduction abnormalities, including QTc prolongation of >480 milliseconds and/or pacemaker or clinically relevant impaired cardiovascular function.
• Has hypertension uncontrolled by medication
• Has retinal degenerative disease (hereditary retinal degeneration or age-related macular degeneration), history of uveitis, or history of retinal vein occlusion (RVO) or any eye condition that would be considered a risk factor for RVO (e.g., uncontrolled glaucoma or ocular hypertension).
• Has known active central nervous system (CNS) metastases unless previously radiotherapy treated, stable by CT scan for at least 3 months without evidence of cerebral edema and no requirements for corticosteroids or anticonvulsants.
• History of difficulty swallowing, malabsorption or other chronic gastro-intestinal disease, or conditions that may hamper compliance and/or absorption of the tested product.
• Known human immunodeficiency virus (HIV) positivity, active hepatitis C, or active hepatitis B.
• Has undergone surgical intervention within 28 days from Day 1 of trial drug treatment.
• Has received extensive prior radiotherapy on more than 30% of bone marrow reserves, or prior bone marrow/stem cell transplantation within 5 years from Day 1 of trial drug treatment.
• Has history of any other significant medical disease such as major gastric or small bowel surgery, recent drainage of significant volumes of ascites or pleural effusion or has a psychiatric condition that might impair the subject well-being or preclude full participation in the trial.
• Has known hypersensitivity to dacarbazine.
• Is a pregnant or nursing female.
• Participated in another clinical trial within the past 28 days.
• Has creatine phosphokinase (CPK) level at baseline National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Grade >=2 (i.e > 2.5 * ULN), and/or has a previous history of myositis or rhabdomyolysis.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Merck KGaA, Darmstadt, Germany

INDUSTRY

Sponsor Role: collaborator

EMD Serono

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Study Director

Role: STUDY_DIRECTOR

EMD Serono Inc., a business of Merck KGaA, Darmstadt, Germany

Locations

Research Site

Birmingham, Alabama, United States

Research Site

Tucson, Arizona, United States

Research Site

San Francisco, California, United States

Research Site

Miami Beach, Florida, United States

Research Site

Orlando, Florida, United States

Research Site

Maywood, Illinois, United States

Research Site

Indianapolis, Indiana, United States

Research Site

Boston, Massachusetts, United States

Please contact the US Medical Information in

Rockland, Massachusetts, United States

Research Site

St Louis, Missouri, United States

Research Site

Morristown, New Jersey, United States

Research Site

New York, New York, United States

Research Site

Columbus, Ohio, United States

Research Site

Dallas, Texas, United States

Research Site

Madison, Wisconsin, United States

Research Site

Adelaide, SA, , Australia

Research Site

Albury/Wodonga, , Australia

Research Site

Auchenflower, , Australia

Research Site

Box Hill, , Australia

Research Site

Greenslopes, , Australia

Research Site

Herston, , Australia

Research Site

Malvern, , Australia

Research Site

North Sydney, , Australia

Research Site

Prahran, , Australia

Research Site

Wendouree, , Australia

Research Site

Woodville South, , Australia

Research site

Woolloongabba, , Australia

Research Site

Brussels, , Belgium

Research Site

Edegem, , Belgium

Research Site

Bordeaux, , France

Research Site

Brest, , France

Research Site

Dijon, , France

Research Site

Lille, , France

Research Site

Lyon, , France

Research Site

Marseille, , France

Research Site

Montpellier, , France

Research Site

Nantes, , France

Research Site

Paris, , France

Research Site

Pierre-Bénite, , France

Research Site

Rennes, , France

Research Site

Toulouse, , France

Research Site

Villejuif, , France

Research Site

Augsburg, , Germany

Research Site

Berlin, , Germany

Research Site

Bonn, , Germany

Research Site

Buxtehude, , Germany

Research Site

Cologne, , Germany

Research site

Düsseldorf, , Germany

Research Site

Erlangen, , Germany

Research Site

Essen, , Germany

Research Site

Frankfurt am Main, , Germany

Research Site

Hamburg, , Germany

Research Site

Hanover, , Germany

Research Site

Kiel, , Germany

Research Site

Leipzig, , Germany

Research Site

Magdeburg, , Germany

Research Site

Mainz, , Germany

Research site

München, , Germany

Research Site

Münster, , Germany

Research Site

Plauen, , Germany

Research Site

Tübingen, , Germany

Research Site

Würzburg, , Germany

Research Site

Jerusalem, , Israel

Research Site

Ramat Gan, , Israel

Research Site

Tel Aviv, , Israel

Research Site

Bari, , Italy

Research Site

Genova, , Italy

Research Site

Meldola - FC, , Italy

Research Site

Milan, , Italy

Research Site

Napoli, , Italy

Research Site

Padua, , Italy

Research Site

Roma, , Italy

Research Site

Siena, , Italy

Research Site

Groningen, , Netherlands

Research Site

Rotterdam, , Netherlands

Research Site

Utrecht, , Netherlands

Research Site

Christchurch, , New Zealand

Research Site

Hamilton, , New Zealand

Research Site

Palmerston North, , New Zealand

Research Site

Tauranga, , New Zealand

Research Site

Durban, , South Africa

Research Site

Johannesburg, , South Africa

Research Site

Pietermaritzburg, , South Africa

Research Site

Pretoria, , South Africa

Research Site

Badalona, , Spain

Research Site

Barcelona, , Spain

Research Site

L'Hospitalet de Llobregat, , Spain

Research Site

Madrid, , Spain

Research Site

Majadahonda, , Spain

Research Site

Málaga, , Spain

Research Site

Pamplona, , Spain

Research Site

Seville, , Spain

Research Site

Gothenburg, , Sweden

Research Site

Stockholm, , Sweden

Research Site

Basel, , Switzerland

Research Site

Zurich, , Switzerland

Research Site

Cambridge, , United Kingdom

Research Site

London, , United Kingdom

Research Site

Manchester, , United Kingdom

Research Site

Newcastle upon Tyne, , United Kingdom

Research Site

Southampton, , United Kingdom

Countries

United States; Australia; Belgium; France; Germany; Israel; Italy; Netherlands; New Zealand; South Africa; Spain; Sweden; Switzerland; United Kingdom

References

Lebbe C, Dutriaux C, Lesimple T, Kruit W, Kerger J, Thomas L, Guillot B, Braud F, Garbe C, Grob JJ, Loquai C, Ferraresi V, Robert C, Vasey P, Conry R, Isaacs R, Espinosa E, Schueler A, Massimini G, Dreno B. Pimasertib Versus Dacarbazine in Patients With Unresectable NRAS-Mutated Cutaneous Melanoma: Phase II, Randomized, Controlled Trial with Crossover. Cancers (Basel). 2020 Jun 29;12(7):1727. doi: 10.3390/cancers12071727.

Reference Type: DERIVED

PMID: 32610581 (View on PubMed)

Other Identifiers

2012-002669-37

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

EMR 200066-007

Identifier Type: -

Identifier Source: org_study_id